“Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Advanced Fibrosis in Type 2 Diabetes Mellitus Patients”, Pjmcr, vol. 5, no. 1, pp. 163–174, Jan. 2026, doi: 10.5281/zenodo.18345788.